Thailand's decision to provide free gender-affirming hormone therapy under its universal healthcare scheme has prompted questions about how the National Health Security Office (NHSO) should prioritise spending amid growing pressure on the public health system.
The programme, which covers around 20,000 transgender people at an estimated cost of 145 million baht annually, began distributing medicines through participating healthcare units nationwide on June 10.
